Effect of Yucca Schidigera Extract on Salmonella Enteritidis-Infected Poultry Compared with Fosfomycin Drug

Document Type : Original Article

Authors

1 Senior researcher of pharmacology, Animal Health Research institute, Agriculture Research centre

2 Immunology Department, Animal Health Research Institute (AHRI), Agricultural Research Centre (ARC), Dokki, Giza

3 3Reference Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, Agriculture Research Centre (ARC)Dokki, Giza12618, Egypt

Abstract

The research aimed to investigate the impact of Yucca schidigera extract on Salmonella enteritidis -infected poultry compared to the fosfomycin drug. 140 salmonella free chickens were classified into first control-negative group and four Salmonella infected groups at nine days old (1×108 CFU/ml orally) orally. The second group acts as a positive group, while the 3rd, 4th, and 5th groups were treated with fosfomycin, Yucca schidigera extract, and both of them, respectively. Fosfomycin was administered at 5 days post infection at 14d old for five days. Yucca extract was administered from day one until the end of the experimental period (42d). The re-isolation of salmonella from the all treated groups after 35 days was negative. Fifth group showed normal liver function enzymes, urea and creatinine; maintain albumin and globulin at normal levels from 14 to 35 days; and keep the normal values of total antioxidants. The fourth and fifth groups displayed highly significant levels of lysozyme at 21 days old followed by a non-significant decrease at 28 and 35 days old, and decrease in relative fold changes of IL-6 compared with the second group. In the fifth group, the hemagglutination inhibition antibody titer was non-significantly higher at 21 and 28 days old, and there was a significant increase at 35 and 42 days old in comparison with the fourth group. Therefore, Yucca schidigera is a safe, effective, biocompatible, and cost-efficient alternative natural product that could be used for the treatment of salmonellosis by enhancement immune response and activated antioxidative capacity.

Keywords

Main Subjects



Articles in Press, Corrected Proof
Available Online from 02 October 2024
  • Receive Date: 24 July 2024
  • Revise Date: 11 September 2024
  • Accept Date: 14 September 2024